Search

Author/Creator Mark, Michael

11. SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial. Issue 26 (10th September 2021)

Authors:
Rothschild, Sacha I.; Zippelius, Alfred; Eboulet, Eric I.; Savic Prince, Spasenija; Betticher, Daniel; Bettini, Adrienne; Früh, Martin; Joerger, Markus; Lardinois, Didier; Gelpke, Hans; Mauti, Laetitia A.; Britschgi, Christian; Weder, Walter; Peters, Solange; Mark, Michael; Cathomas, Richard; Och...
Journal:
Journal of clinical oncology
Issue:
Volume 39:Issue 26(2021)
Page Start:
2872
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

12. Urinary dipeptidyl peptidase‐4 protein is increased by linagliptin and is a potential predictive marker of urine albumin‐to‐creatinine ratio reduction in patients with type 2 diabetes. Issue 8 (6th May 2021)

Authors:
Klein, Thomas; Tammen, Harald; Mark, Michael; Benetti, Elisa; Delić, Denis; Schepers, Cornelia; von Eynatten, Maximilian
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 23:Issue 8(2021)
Page Start:
1968
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗